The effectiveness clears the path to pricing, expected within 1-2 days. The tiny $4M market cap and going-concern warning make the offering highly dilutive. Watch for the pricing announcement (424B4 filing) — the actual terms may differ from the assumed $1.52 price. If the stock trades near or below the offering price pre-pricing, the deal may be repriced lower, increasing dilution. A successful close removes near-term bankruptcy risk but leaves shareholders with severe overhang.
Price Chart
Executive Summary
The SEC declared bioAffinity Technologies' S-1 registration statement (File No. 333-296764) effective on June 16, 2026, enabling the company to proceed with a best-efforts public offering of up to 2,631,579 shares at $1.52/share, targeting ~$3.4M in net proceeds. With a $4M market cap, a going-concern warning, declining consolidated revenue, and only $3.1M cash on hand, this offering is a high-stakes capital raise to fund operations, and the effectiveness now opens the door to near-term pricing and potentially severe dilution.
Key Facts
- Effectiveness declared on June 16, 2026 for S-1 File No. 333-296764
- Offering size: up to 2,631,579 shares of common stock and pre-funded warrants at assumed price of $1.52 per share
- Target net proceeds: approximately $3.4 million for working capital
- Company has a going-concern warning from its auditor
- Cash on hand as of March 31, 2026: $3.1 million
- Accumulated deficit: $72.2 million
- Consolidated Q1 2026 revenue declined 36% YoY to $1.4 million (CyPath Lung unit sales grew 146% but overall revenue fell)
- Market capitalization is approximately $4 million (as of filing date context)
- The company also has a resale registration for up to 497,483 shares from selling stockholders (warrant/conversion shares) which is also now effective
Financial Impact
Approximately $3.4 million in gross proceeds before expenses; subsequent dilution of up to ~66% relative to pre-offering shares outstanding (2.63M new shares vs. ~4M pre-offering based on a ~$4M market cap at $1.52/share).
Risk Factors
- Severe dilution: new shares could outnumber existing shares by ~66%
- Going-concern risk remains even after the raise; $3.4M may only fund a few quarters at current burn rate
- Resale of up to ~497K shares from selling stockholders overhang adds further selling pressure
- CyPath Lung unit growth may not offset the revenue decline if the core business continues to shrink
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002028 |
| Document: 9999999995-26-002028-index.html | 9999999995-26-002028 |
| Document: 9999999995-26-002028.txt | 9999999995-26-002028 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEF 14A | $2.81 | awaiting T+1 | — | $2.99 (+6.41%) |
Oct 15, 2026 12d ago | 8-K | $3.96 $3.73 | ▼ −5.81% | ▼ −4.70% | $2.99 (−24.49%) |
Oct 13, 2026 14d ago | 8-K | $3.63 $3.56 | ▼ −1.79% | ▼ −0.71% | $2.99 (−17.52%) |
Oct 9, 2026 17d ago | 8-K | $3.90 $3.63 | ▲ +7.05% | ▲ +7.04% | $2.99 (+23.33%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▲ +17.46% | ▲ +17.40% | $2.99 (+36.72%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 $3.90 | ▼ −17.46% | ▼ −17.40% | $2.99 (−36.72%) |
Oct 8, 2026 19d ago | 8-K | $5.64 $4.73 | ▼ −16.22% | ▼ −16.82% | $2.99 (−46.99%) |
Oct 6, 2026 21d ago | 8-K | $6.06 $6.16 | ▲ +1.65% | ▲ +1.89% | $2.99 (−50.66%) |
Sep 30, 2026 27d ago | 8-K | $6.56 $6.15 | ▼ −6.33% | ▼ −6.50% | $2.99 (−54.42%) |
Sep 22, 2026 5w ago | 8-K | $8.56 $7.94 | ▼ −7.19% | ▼ −6.47% | $2.99 (−65.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers